The longevity industry has no shortage of products focused on healthier aging.
asserted
industry → have → aging
What can be more difficult to find is a clear understanding of why a particular formulation exists, what biological science informed its development, and how its ingredients were selected.
asserted
ingredients → find → development
BioAro Inc. is entering this space with the launch of its precision LONgevity+™ bioactives in the United States and United Kingdom, following its initial launch in Dubai.
asserted
Inc. → enter → Dubai
BioAro’s formulations have been developed through a combination of biotechnology research, scientific literature, biological pathway analysis, formulation science, and artificial intelligence, with the goal of exploring more targeted approaches to healthy aging, longevity, and healthspan.
asserted
formulations → develop → aging
The products are now available through BioAro Drugs, BioAro’s consumer health and longevity platform, which has been funded by Kapoor Wealth Partners, Abu Dhabi.
asserted
which → fund → Partners
Several of BioAro’s LONgevity+™ formulations began as compositions developed by Dr. Anmol S. Kapoor, Founder of BioAro, for his own use after finding that many commercially available products did not meet the level of formulation and scientific rigor he was seeking.
asserted
he → begin → formulation
Those early formulations subsequently became part of a broader research and development effort within the BioAro ecosystem.
asserted
formulations → become → ecosystem
“We didn’t set out to create another supplement company,” said Dr. Anmol S. Kapoor, Founder of BioAro.
asserted
Kapoor → set → BioAro
“The starting point was a simple question: Can we use what we now know about biology, combined with AI and modern research tools, to develop longevity bioactives in a more intelligent way?”
asserted
we → use → way
Rather than examining ingredients only in isolation, BioAro evaluates how compounds may relate to biological pathways and how combinations can be formulated around specific objectives associated with healthy aging, longevity, and healthspan.
uncertain
combinations → examine → aging
Artificial intelligence is increasingly being used across biotechnology and drug discovery, and BioAro is applying AI-assisted research within its consumer-health development process.
asserted
BioAro → use → process
Its research workflow uses AI-assisted analysis to examine scientific literature, biological pathways, molecular relationships, and formulation possibilities, helping researchers navigate a rapidly expanding body of scientific information and identify relationships that warrant further investigation.
asserted
that → use → investigation
“AI doesn’t replace the scientist or the physician,” Dr. Kapoor said.
asserted
Kapoor → replace → scientist
“It gives us the ability to look across an enormous amount of information and ask better questions.
asserted
It → give → questions
The science still has to make sense.”
asserted
science → have → sense
BioAro’s approach reflects the interconnected nature of longevity science.
asserted
approach → reflect → science
Aging involves multiple biological processes, including cellular energy, metabolic regulation, oxidative stress, inflammation, and other mechanisms.
asserted
Aging → involve → energy
The company’s LONgevity+™ portfolio has been developed with this complexity in mind, with an emphasis on looking beyond isolated ingredients.
asserted
portfolio → develop → ingredients
Alongside its longevity portfolio, BioAro has also developed specialized formulations for daily wellness, cognition, energy, physical performance, and recovery through its CREAGEN™ series, including CREAGEN™ Brain Boost, CREAGEN™ Raw Power, CREAGEN™ Pro Power, and CREAGEN™ Femme Energy.
asserted
BioAro → develop → Boost
The range extends BioAro’s formulation approach across different wellness and performance goals.
asserted
range → extend → goals
BioAro Drugs also features BioAro Intelligence, one of the company’s flagship AI-assisted consumer experiences, powered by Xevyo AI.
asserted
Drugs → feature → AI
BioAro Intelligence is designed to help users begin with a health or wellness goal and explore relevant protocols — structured combinations of products, formulas, ingredients, and supporting scientific context organized around that objective.
asserted
users → design → objective
The broader BioAro ecosystem spans precision health, genomics, multi-omics, microbiome science, diagnostics, artificial intelligence, drug discovery and development, and longevity.
asserted
ecosystem → span → health
The company is developing technologies and platforms designed to connect these different layers of biological information rather than treating them as isolated data points.
asserted
company → develop → points
Genomic and microbiome information can provide insight into an individual’s underlying biology, while advanced diagnostics can add information about measurable biomarkers and physiological processes.
asserted
diagnostics → provide → biomarkers
AI can assist in interpreting increasingly complex biological datasets, while drug-discovery platforms can help researchers explore potential therapeutic opportunities.
asserted
researchers → assist → opportunities
“The future of longevity will not be about finding one magic ingredient,” said Dr. Kapoor.
asserted
Kapoor → find → ingredient
“It will be about understanding the individual, understanding the biology, and then using that information intelligently.”
asserted
It → understand → information
The expansion into the United States and United Kingdom follows BioAro’s initial launch in Dubai and brings its LONgevity+™ portfolio into two major global consumer-health markets.
asserted
expansion → follow → markets
The company also plans to expand BioAro Drugs beyond its current bioactive portfolio to include peptide-based products, pharmaceutical offerings, and online consultations, subject to applicable regulatory requirements, creating a broader platform connecting consumers with longevity products, scientific information, and professional healthcare services.
asserted
company → plan → products
BioAro expects to work with physicians, researchers, biotechnology companies, pharmaceutical organizations, manufacturers, and other strategic partners as the platform develops.
asserted
platform → expect → physicians
“This is only the beginning of what we are building,” said Dr. Kapoor.
asserted
Kapoor → build → what
“We see an opportunity to bring bioactives, peptides, pharmaceuticals, diagnostics, and consultations together within a connected longevity platform, while working with partners across healthcare, biotechnology, and life sciences.
asserted
We → see → healthcare
For BioAro, the launch represents a broader effort to connect the rapidly developing fields of AI, biotechnology, precision health, and longevity within an integrated health ecosystem.
asserted
launch → represent → ecosystem
About BioAro
BioAro is a global precision-health and biotechnology ecosystem focused on applying advanced science, artificial intelligence, and biological data to improve how health, healthy aging, and longevity are understood and managed.
asserted
health → focus → science
Its ecosystem spans precision health, genomics, multi-omics, microbiome science, diagnostics, AI-assisted biological analysis, drug discovery and development, and LONgevity+™ bioactives.
asserted
ecosystem → span → health
Through its laboratory and technology platforms, BioAro is working to connect information from the genome, microbiome, biomarkers, and other biological systems to develop a more integrated understanding of individual biology.
asserted
BioAro → work → biology
Its consumer health portfolio includes LONgevity+™ bioactives, the CREAGEN™ series, and BioAro Intelligence powered by Xevyo AI, while its broader initiatives extend into diagnostics, biological analysis, and drug discovery.
asserted
initiatives → include → diagnostics
BioAro Drugs is funded by Kapoor Wealth Partners, Abu Dhabi, supporting the development and international expansion of BioAro’s consumer health and longevity platform.
asserted
Drugs → fund → platform
BioAro’s broader vision is to build a connected precision-health ecosystem where biological data and diagnostics generate insights, AI assists in interpreting complex information, drug discovery explores potential therapeutic opportunities, and precision interventions provide additional tools for supporting health and longevity.
asserted
interventions → build → health
…and 1 more, not listed.
The Aporia
